Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinnaoning Capsule for Chronic Stable Angina
NCT03914131Phase 4Unknown
- Sponsor
- Beijing Duheng for Drug Evaluation and Research
- Start
- May 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Xinnaoning in angina pectoris (2 arms), sponsored by Beijing Duheng for Drug Evaluation and Research. Primary endpoint: Changes of curative effect of angina pectoris symptoms at 12 weeks. Status: unknown.
02
Drugs
Xinnaoning
03
Conditions
angina pectoris
Beyond the preview
Go deeper on NCT03914131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914131.